Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability and safety of Ig VENA at high infusion rates
2013-000961-36Phase 3Completed
- Sponsor
- Kedrion Biopharma
- Start
- Aug 2013
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Gamimune-N in Immunogenetic disorder, secondary immunodeficiency (SID) and immune thrombocytopenia (ITP), sponsored by Kedrion Biopharma. Started Aug 2013; status: completed.
02
Drugs
Gamimune-N
03
Conditions
Immunogenetic disordersecondary immunodeficiency (SID)immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2013-000961-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000961-36.